- Home
- FEMY vs IGC Comparison
FEMY vs IGC Comparison
Compare FEMY & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEMY
- IGC
- Stock Information
- Founded
- FEMY 2004
- IGC 2005
- Country
- FEMY United States
- IGC United States
- Employees
- FEMY N/A
- IGC N/A
- Industry
- FEMY Medical/Dental Instruments
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- FEMY Health Care
- IGC Health Care
- Exchange
- FEMY Nasdaq
- IGC Nasdaq
- Market Cap
- FEMY 12.5M
- IGC 39.8M
- IPO Year
- FEMY 2021
- IGC N/A
- Fundamental
- Price
- FEMY $0.37
- IGC $0.42
- Analyst Decision
- FEMY Strong Buy
- IGC Strong Buy
- Analyst Count
- FEMY 3
- IGC 2
- Target Price
- FEMY $7.33
- IGC $4.00
- AVG Volume (30 Days)
- FEMY 2.9M
- IGC 1.4M
- Earning Date
- FEMY 11-11-2025
- IGC 11-11-2025
- Dividend Yield
- FEMY N/A
- IGC N/A
- EPS Growth
- FEMY N/A
- IGC N/A
- EPS
- FEMY N/A
- IGC N/A
- Revenue
- FEMY $1,887,016.00
- IGC $1,327,000.00
- Revenue This Year
- FEMY $103.55
- IGC $15.26
- Revenue Next Year
- FEMY $148.13
- IGC $3.41
- P/E Ratio
- FEMY N/A
- IGC N/A
- Revenue Growth
- FEMY 98.61
- IGC 24.95
- 52 Week Low
- FEMY $0.31
- IGC $0.25
- 52 Week High
- FEMY $1.80
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- FEMY 28.85
- IGC 56.04
- Support Level
- FEMY $0.35
- IGC $0.38
- Resistance Level
- FEMY $0.57
- IGC $0.47
- Average True Range (ATR)
- FEMY 0.05
- IGC 0.04
- MACD
- FEMY 0.01
- IGC -0.00
- Stochastic Oscillator
- FEMY 22.70
- IGC 34.25
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.